IDEAYA Biosciences

IDEAYA Biosciences

IDYA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +34.5% in FY2025

Yujiro S. Hata is the CEO of IDEAYA Biosciences and was paid $9.5M in FY2025 (Dec), down 44%.

Pay$100 in the stock at the end of FY20 → $247
CEO pay is from each IDEAYA Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Yujiro S. HataFY2025
  2. 2Joshua Bleharski, Ph.D.FY2025
  3. 3Darrin M. Beaupre, M.D., Ph.D.FY2025
  4. 4Michael A. White, Ph.D.FY2025
  5. 5Andres Ruiz BrisenoFY2025
  6. 6Douglas B. SnyderFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

IDEAYA Biosciences paid its 6 named executives $23.1M in total in FY2025 (Dec). CEO Yujiro S. Hata was paid $9.5M of that.

Name
Yujiro S. HataPresident and Chief Executive Officer
Joshua Bleharski, Ph.D.Chief Financial OfficerNot disclosedNot disclosed
Darrin M. Beaupre, M.D., Ph.D.Chief Medical Officer
Michael A. White, Ph.D.Chief Scientific Officer
Andres Ruiz BrisenoChief Accounting Officer
Douglas B. SnyderChief Legal OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers21

See all

The FY2023 (Dec) proxy of IDEAYA Biosciences names 21 peer companies for pay. Pay versus performance data of IDEAYA Biosciences for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Jeffrey L. Stein, Ph.D.Director · 10 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
  • Garret M. Hampton, Ph.D.Director · 5 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

  1. Pay
    IDEAYA Biosciences CEO pay fell 44% to $9.5M. The stock rose 35% in FY2025 (Dec).
    DEF 14A
  2. Pay
    IDEAYA Biosciences Chief Scientific Officer pay fell 38% to $3.3M. The stock rose 35% in FY2025 (Dec).
    DEF 14A
  3. Pay
    IDEAYA Biosciences Division head pay fell 45% to $3.3M. The stock rose 35% in FY2025 (Dec).
    DEF 14A
  4. Pay
    IDEAYA Biosciences CAO pay fell 51% to $1.7M. The stock rose 35% in FY2025 (Dec).
    DEF 14A
  5. Pay
    IDEAYA Biosciences CEO pay rose 182% to $16.9M. The stock fell 28% in FY2024 (Dec).
    DEF 14A
  6. Pay
    IDEAYA Biosciences CEO pay fell 14% to $3.3M. The stock fell 23% in FY2022 (Dec).
    DEF 14A
  7. Pay
    IDEAYA Biosciences Chief Scientific Officer pay rose 95% to $5.4M. The stock fell 28% in FY2024 (Dec).
    DEF 14A
  8. Pay
    IDEAYA Biosciences Chief Scientific Officer pay fell 58% to $1.5M. The stock fell 23% in FY2022 (Dec).
    DEF 14A
  9. Pay
    IDEAYA Biosciences General counsel pay rose 139% to $4.5M. The stock fell 28% in FY2024 (Dec).
    DEF 14A
  10. Pay
    IDEAYA Biosciences Division head pay rose 235% to $6.1M. The stock fell 28% in FY2024 (Dec).
    DEF 14A
  11. Pay
    IDEAYA Biosciences CAO pay rose 138% to $3.4M. The stock fell 28% in FY2024 (Dec).
    DEF 14A
  12. Pay
    IDEAYA Biosciences CEO pay rose 80% to $6.0M. The stock rose 96% in FY2023 (Dec).
    DEF 14A
  13. Pay
    IDEAYA Biosciences Former CFO pay rose 51% to $2.2M. The stock rose 96% in FY2023 (Dec).
    DEF 14A
  14. Pay
    IDEAYA Biosciences Former CFO pay fell 18% to $1.5M. The stock fell 23% in FY2022 (Dec).
    DEF 14A
  15. Pay
    IDEAYA Biosciences Chief Scientific Officer pay rose 85% to $2.8M. The stock rose 96% in FY2023 (Dec).
    DEF 14A
  16. Pay
    IDEAYA Biosciences Division head pay fell 29% to $1.8M. The stock rose 96% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KFeb 17, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KFeb 18, 2025FY2024
Proxy statementDEF 14AApr 19, 2024FY2023
Annual report10-KFeb 20, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data